BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18923961)

  • 1. Serum beta-amyloid correlates with neuropsychological impairment.
    Luis CA; Abdullah L; Paris D; Quadros A; Mullan M; Mouzon B; Ait-Ghezala G; Crawford F; Mullan M
    Neuropsychol Dev Cogn B Aging Neuropsychol Cogn; 2009 Mar; 16(2):203-18. PubMed ID: 18923961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of Alzheimer's disease amyloid-β in plasma by hemodialysis and its relation to cognitive functions.
    Kitaguchi N; Kawaguchi K; Nakai S; Murakami K; Ito S; Hoshino H; Hori H; Ohashi A; Shimano Y; Suzuki N; Yuzawa Y; Mutoh T; Sugiyama S
    Blood Purif; 2011; 32(1):57-62. PubMed ID: 21346337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory complainers.
    Bates KA; Sohrabi HR; Rodrigues M; Beilby J; Dhaliwal SS; Taddei K; Criddle A; Wraith M; Howard M; Martins G; Paton A; Mehta P; Foster JK; Martins IJ; Lautenschlager NT; Mastaglia FL; Laws SM; Gandy SE; Martins RN
    J Alzheimers Dis; 2009; 17(2):305-18. PubMed ID: 19363264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-associated depression: a prodromal depression of Alzheimer disease?
    Sun X; Steffens DC; Au R; Folstein M; Summergrad P; Yee J; Rosenberg I; Mwamburi DM; Qiu WQ
    Arch Gen Psychiatry; 2008 May; 65(5):542-50. PubMed ID: 18458206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
    Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
    Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
    Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
    Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
    Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels.
    Abdullah L; Paris D; Luis C; Quadros A; Parrish J; Valdes L; Keegan AP; Mathura V; Crawford F; Mullan M
    Neurosci Lett; 2007 Nov; 428(2-3):53-8. PubMed ID: 17964720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abeta(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels.
    Christensen R; Marcussen AB; Wörtwein G; Knudsen GM; Aznar S
    Exp Neurol; 2008 Mar; 210(1):164-71. PubMed ID: 18053988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of indexes in the interpretation of cerebrospinal fluid analyses.
    Verbeek MM; Sjögren JM
    Neurobiol Aging; 2010 Sep; 31(9):1654; discussion 1655. PubMed ID: 20395016
    [No Abstract]   [Full Text] [Related]  

  • 12. Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease.
    Diniz BS; Teixeira AL; Ojopi EB; Talib LL; Mendonça VA; Gattaz WF; Forlenza OV
    J Alzheimers Dis; 2010; 22(4):1305-11. PubMed ID: 20930310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease.
    Irizarry MC; Gurol ME; Raju S; Diaz-Arrastia R; Locascio JJ; Tennis M; Hyman BT; Growdon JH; Greenberg SM; Bottiglieri T
    Neurology; 2005 Nov; 65(9):1402-8. PubMed ID: 16275827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
    Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
    Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease.
    González-Martínez Á; Rosado B; Pesini P; Suárez ML; Santamarina G; García-Belenguer S; Villegas A; Monleón I; Sarasa M
    Exp Gerontol; 2011 Jul; 46(7):590-6. PubMed ID: 21377518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment.
    Hansson O; Zetterberg H; Vanmechelen E; Vanderstichele H; Andreasson U; Londos E; Wallin A; Minthon L; Blennow K
    Neurobiol Aging; 2010 Mar; 31(3):357-67. PubMed ID: 18486992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy.
    Gurol ME; Irizarry MC; Smith EE; Raju S; Diaz-Arrastia R; Bottiglieri T; Rosand J; Growdon JH; Greenberg SM
    Neurology; 2006 Jan; 66(1):23-9. PubMed ID: 16401840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine.
    Blasko I; Jellinger K; Kemmler G; Krampla W; Jungwirth S; Wichart I; Tragl KH; Fischer P
    Neurobiol Aging; 2008 Jan; 29(1):1-11. PubMed ID: 17055615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
    Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.